[PMID: 26439496] [Cancer Cell]
Many clinically relevant RNA editing events are in noncoding regions. Nonsynonymous RNA editing may affect drug sensitivity. “A-to-I editing is a major source of mRNA variability in breast and other cancers. RNA editing is globally controlled by tumor interferon and ADAR copy number.” [PMID:26440892] “Extensive editing in cancer introduces RNA diversity or RNA mutations. RNA modification events in tumors are as abundant as genomic DNA mutations.” [PMID: 26440895] Will Yoav Gilad and Jonathan Pritchard comment on this?